SEQENS CDMO Revenue and Competitors
Estimated Revenue & Valuation
- SEQENS CDMO's estimated annual revenue is currently $23.1M per year.
- SEQENS CDMO's estimated revenue per employee is $201,000
Employee Data
- SEQENS CDMO has 115 Employees.
- SEQENS CDMO grew their employee count by -17% last year.
SEQENS CDMO's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Customer Service Officer | Reveal Email/Phone |
2 | Head BU Supply Chain - Generics BU | Reveal Email/Phone |
3 | Head Tech Transfer and Kilo Lab | Reveal Email/Phone |
4 | Head Sales Europe & Asia - Category Manager Custom Synthesis Small Molecules & Pharmachemicals | Reveal Email/Phone |
5 | Associate Director CMC | Reveal Email/Phone |
6 | Business Support Officer | Reveal Email/Phone |
7 | QA Director, QP | Reveal Email/Phone |
8 | Supply Chain Manager | Reveal Email/Phone |
9 | Supply chain Manager | Reveal Email/Phone |
10 | QC Laboratory Manager | Reveal Email/Phone |
SEQENS CDMO Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $391.7M | 2798 | -3% | $200M | N/A |
What Is SEQENS CDMO?
Emergence of a new global CDMO Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI Synthesis in the United States – have joined forces as Seqens CDMO (formerly Novacap) to offer world-class Drug Substance Development and Manufacturing services to the pharmaceutical industry. With three R&D centers, six cGMP / FDA inspected production sites in Europe and the United States supported by two manufacturing sites for the production of critical intermediates and Regulatory Starting Materials (RSMs), the group offers a powerful manufacturing network employing approximately 1200 persons capable to embrace complexity in developing, industrializing and manufacturing complex molecular entities.
keywords:N/A
N/A
Total Funding
115
Number of Employees
$23.1M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SEQENS CDMO News
Increases R&D capability and productivity in the U.S. and builds on merger with CDMO Wavelength Pharmaceuticals. 03.21.22. SEQENS, a manufacturer of active...
French CDMO Seqens has signed a multimillion-dollar deal to add an R&D laboratory in Devens, Mass., which is about an hour from its US manufacturing...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $25.3M | 115 | 22% | N/A |
#2 | $16.1M | 115 | 7% | N/A |
#3 | $16.1M | 115 | -2% | $127.7M |
#4 | $16.7M | 115 | 67% | N/A |
#5 | $37.1M | 115 | 25% | N/A |